title: Bevacizumab followed by chemotherapy is potential therapy for gastric cancer.
abstract: OBJECTIVE
  To investigate the antitumor effects of the angiogenesis inhibitor bevacizumab combined with chemotherapy, and the application of in vivo imaging technology of growth of fluorescence-labelled gastric cancer (GC) in nude mice.
  
  
  METHODS
  Twenty-five nude mice were randomly divided into 5 groups (A-E). Subcutaneous xenograft of human MGC803 cells was transplanted to nude mice, followed by different treatments for the groups, including A (bevacizumab combined with chemotherapy), B (24-h chemotherapy with FP followed by bevacizumab), C (bevacizumab 24-h followed by FP chemotherapy), D (bevacizumab only) and E (normal saline). Then, dynamic variation of tumor growth during 4 weeks was evaluated by calculating the tumor inhibition rate and fluorescence signal strength by in vivo imaging system.
  
  
  RESULTS
  After 28-day treatment, fluorescence signal strength in the groups A-D changed significantly compared with the E (control) group, while tumor inhibition rate in C group was highest (68.42%). Furthermore, on the 4th week, the fluorescence signal value in C group was lowest.
  
  
  CONCLUSIONS
  Administration of bevacizumab followed by chemotherapy was more effective therapeutic method for GC. The in vivo imaging could show off dynamic variation of tumors and was a sensitive and objective detection method.
authors.affiliation: Department of Medical Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, China.
authors.forename: Yalei
authors.initials: Y
authors.lastname: Lv
authors.forename: Lina
authors.initials: L
authors.lastname: Song
authors.forename: Liang
authors.initials: L
authors.lastname: Chang
authors.forename: Yan
authors.initials: Y
authors.lastname: Liu
authors.forename: Xiaolin
authors.initials: X
authors.lastname: Zhang
authors.forename: Yudong
authors.initials: Y
authors.lastname: Wang
authors.forename: Long
authors.initials: L
authors.lastname: Wang
authors.forename: Wei
authors.initials: W
authors.lastname: Liu
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D000068258:Bevacizumab / Q000494:pharmacology*; D045744:Cell Line, Tumor; D017930:Genes, Reporter; D006801:Humans; D008163:Luminescent Measurements; D008297:Male; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D061848:Optical Imaging / Q000379:methods; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D013997:Time Factors; D014162:Transfection; D047368:Tumor Burden / Q000187:drug effects; D023041:Xenograft Model Antitumor Assays
chemical_list: D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab